Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) was the target of a large growth in short interest during the month of August. As of August 31st, there was short interest totalling 3,889,264 shares, a growth of 32.8% from the August 15th total of 2,927,894 shares. Approximately 7.7% of the company’s stock are short sold. Based on an average daily trading volume, of 856,396 shares, the days-to-cover ratio is presently 4.5 days.

In other news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The stock was sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider now directly owns 17,500 shares of the company’s stock, valued at approximately $105,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 5.50% of the company’s stock.

A number of institutional investors have recently bought and sold shares of TTPH. AXA purchased a new stake in Tetraphase Pharmaceuticals during the second quarter valued at $132,000. Teza Capital Management LLC increased its position in Tetraphase Pharmaceuticals by 8.9% during the first quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,281 shares during the last quarter. Citadel Advisors LLC increased its position in Tetraphase Pharmaceuticals by 18.6% during the first quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,496 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in Tetraphase Pharmaceuticals during the second quarter valued at $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the last quarter. Institutional investors own 41.73% of the company’s stock.

Shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) opened at 6.94 on Friday. Tetraphase Pharmaceuticals has a one year low of $3.11 and a one year high of $9.93. The stock’s market cap is $354.31 million. The company has a 50-day moving average price of $6.28 and a 200 day moving average price of $7.27.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm’s revenue was up 28.2% compared to the same quarter last year. During the same quarter last year, the company posted ($0.47) EPS. Equities research analysts expect that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current year.

TTPH has been the subject of several research analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $13.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Tuesday. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research report on Wednesday, August 9th. HC Wainwright initiated coverage on Tetraphase Pharmaceuticals in a research report on Tuesday, July 11th. They set a “buy” rating and a $15.00 target price for the company. BidaskClub raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $10.88.

ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals, Inc. (TTPH) Short Interest Update” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/16/tetraphase-pharmaceuticals-inc-ttph-short-interest-update.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.